BRK Inhibitors
1 drugsAbout BRK
BRK (breast tumor kinase) is an intracellular non-receptor tyrosine kinase involved in cell growth, proliferation, and survival signaling pathways. Aberrant BRK expression in various cancers has made it a therapeutic target of interest, though its precise physiological role is still under investigation.
The rationale for targeting BRK stems from its involvement in cancer-related signaling pathways. However, there is currently no genetic evidence available linking BRK to specific diseases, which limits confidence in target validation.
BRK is currently targeted by one FDA-approved small molecule drug, CAPRELSA (vandetanib), developed by Sanofi. This single approval highlights the early stage of BRK-directed drug development in oncology.
Top BRK Drugs
Sanofi is the only company with an approved drug targeting BRK.
Low competition may present an opportunity, but also indicates higher risk and uncertainty in the target's viability.
BRK Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BRK, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies and potentially improve efficacy.
BRK Clinical Trials 52 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BRK. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 14 | 9 | 0 | 61% |
| Phase 2 | 24 | 15 | 7 | 2 | 68% |
| Phase 3 | 4 | 2 | 1 | 1 | 67% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
BRK Drug Approval Timeline (2011 - 2011)
The first and only drug, CAPRELSA, was approved in 2011.
The lack of recent approvals suggests potential challenges in developing successful BRK-targeting therapies, requiring careful consideration.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BRK. A trial counts if an approved drug acting on BRK is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.